Right off the top of my head...
1. The general science involved in Chaperones and their IP in this space
2. Migalastat results and advantages over current SOC
3. Partnership with Biogen and potentials with Parkinson
4. Fits the mold of a acquisition target common with smaller bios (but obviously pure speculation)
5. A rock steady CEO with deep skin in the game
I am not underestimating him and if it never gets to 6, I am fine. I said I buy IF it gets there. if not, I am fine with that too. but I yet to find a single reason for this go any higher.
....But I honestly feel this stock could be between 14 and 16 in two to four months...
feeling has no place in the market. Tell us why fold should be between 14-16.
Always harder to pick your chips up off the table and walk away when you are already winning right?
You feel like you are playing with the "house's" money at that point so why not ramp it up?
I'm kinda feeling that way about FOLD right now...
I'm long and up very big....and should probably not be too greedy and take some off the table.
But I honestly feel this stock could be between 14 and 16 in two to four months...
My gut is telling me two different things!!!
I read the abstracts and the posters. They seem to have a potential in the future, but for now it feels like John is running around trying to get higher pps via sympathy. That only works for so long. I think FOLD has lost any team to go above 8. I can see it in low 7s and likely 6 soon. I will buy if it gets there. if not, good luck
they are giving several interviews and attending conferences, so I see the stock sustained and up steadly. Next conference is in 2 weeks: Fabry Disease:
Long-Term Efficacy and Safety of Migalastat Compared to Enzyme Replacement Therapy in Fabry Disease: Phase 3 Study Results -- Derralynn Hughes, DPhil, University College London (Thursday, February 12 at 9:45 a.m. ET)
Novel Recombinant Human Acid Alpha-Glucosidase with Optimal Glycosylation is Significantly Better than Standard of Care Enzyme Replacement for Glycogen Clearance in Skeletal Muscles of Gaa Knock-out Mice. -- Russell Gotschall, Amicus Therapeutics, Inc. (Tuesday, February 10 at
Sentiment: Strong Buy
frankly, I see fold retreating due to lack of catalysts. I am not short, but won't be surprised to see 6s again soon. you can only milk the cow so much and fold has milked it from 3 to 8 already and they haven't even filed with fda. That's my near term forecast. for long term, fold will likely approach $15-20.
You replaced the batteries in your crystal ball? Nice.,,....,,.. Next thing you'll tell us is your Ouija board is fixed too....
fold is fine, but no immediate catalyst to propel it up. hope of a BO is not a good way to make money. gl as I sit this one out